Redwood AI Signs LOI for AI-Enabled Pathogen Surveillance Initiative in East Africa
Redwood AI Corp. has signed a non-binding letter of intent to collaborate on a pathogen tracking and outbreak intelligence initiative in Central and East Africa, aiming to enhance early detection of infectious diseases using AI.
Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N, WKN: A422EZ) has announced the signing of a non-binding letter of intent (LOI) with Dr. Placide Sesonga of the University of Global Health Equity in Rwanda to explore the development of a regional pathogen tracking and AI-enabled outbreak intelligence initiative across Central and East Africa. This collaboration could mark a significant step in leveraging artificial intelligence to strengthen public health surveillance in a region vulnerable to emerging infectious diseases.
The proposed initiative would focus initially on surveillance regions and mobility corridors in Rwanda and the Democratic Republic of the Congo. The plan combines pathogen monitoring, genomic sequencing, geospatial analytics, and Redwood’s AI-driven predictive intelligence platform to support earlier detection of emerging infectious disease threats. The parties intend to develop project protocols, deployment frameworks, and stakeholder engagement strategies while pursuing potential funding opportunities.
This announcement comes at a critical time when global health systems are increasingly looking to AI for predictive capabilities. The ability to detect and respond to outbreaks earlier could have profound implications for public health, economic stability, and regional security. For Redwood AI, this represents an expansion of its technology into a new application area, potentially opening up new markets and funding sources.
Redwood AI uses advanced artificial intelligence to accelerate chemistry R&D, with the aim of assisting in drug discovery and development, and furthering defense and safety solutions. The company combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up. Its platform is designed to enable faster, more efficient development of new therapies and chemistry-driven applications. This pathogen surveillance initiative aligns with Redwood's broader mission, though it focuses on detection rather than treatment.
Separately, Redwood announced the resignation of Graydon Bensler from its board of directors, effective immediately. No reason was given for the resignation. The company continues to pursue strategic opportunities, including the potential East Africa project.
For more information on Redwood AI, visit the company's newsroom at https://ibn.fm/RDWCF. The full press release is available at https://ibn.fm/4ra9u.